Behind the Scenes: A Key Leadership Shift at Edesa Biotech
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, to lead financial strategy in developing therapies for immuno-inflammatory diseases. Stephen Lemieux transitions to…
Shifting Tides at Edesa Biotech: A New CFO Brings Transformative Vision
The appointment of Peter J. Weiler as CFO marks a strategic shift for Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent Inc.,…
Leadership Shuffle at Edesa Biotech Signals Strategic Advancements
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…
The mRNA Revolution: A New Alliance Promises to Reshape Biopharma Landscape
Wacker Biotech and RNAV8 Bio's collaboration advances mRNA-based therapies, merging manufacturing and mRNA engineering expertise. Wacker Biotech brings pharmaceutical-grade pDNA and protein production capabilities with high-capacity fermentation lines. RNAV8 Bio…
Revolutionizing Medicine: The Unstoppable Alliance Changing mRNA Therapeutics Forever
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…
This Groundbreaking Partnership Might Change the Game for mRNA Therapeutics
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
The Fall of a Biotech Titan: What Happened to AmplifyBio?
AmplifyBio, a promising biotech company based in central Ohio, has closed its operations, despite its ambitious beginnings and significant investments. Founded in 2021 as a gene therapy offshoot from Battelle,…
Unlocking the Next Frontier in Medicine: How a New Alliance Promises to Transform mRNA Therapeutics
Wacker Biotech and RNAV8 Bio have partnered to advance mRNA therapeutics, aiming to revolutionize treatment landscapes for various diseases. Wacker Biotech specializes in microbial fermentation, producing high-quality pharmaceutical proteins and…
Biotech’s Bold Gamble: Can Relay Therapeutics Thrive After Radical Overhaul?
Relay Therapeutics is undergoing significant restructuring, including three layoff rounds within a year, to tackle economic challenges and refocus on key clinical goals. The company has slashed its research budget…
The Unseen Battle Behind Relay Therapeutics’ Bold Restructuring
Relay Therapeutics is undergoing significant changes with workforce reductions and cost-cutting to focus on clinical ambitions. The company has reduced its annual research budget by 75% and cut 70 jobs…